Payment overview · 2025
General Payments
$2,055.01
101 reported records · 16 companies
Healthcare provider profile · identity verified
Mary Ann Sayon
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · YUCCA, VALLEY, CA · NPI 1164028080
Verified facts
What the public records show
CMS Open Payments records show Mary Ann Sayon received $2,055.01 in general payments during 2025 across 101 reported records.
Corcept Therapeutics accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Isturisa, Jardiance, Kerendia, Korlym, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Korlym by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
RECORDATI_RARE_DISEASES_INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISTURISA as an associated drug or biological on 7831 records involving 3061 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Isturisa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $415.30 | 20.2% | 31 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $355.33 | 17.3% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $286.45 | 13.9% | 10 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $215.82 | 10.5% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $166.31 | 8.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $112.00 | 5.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.59 | 5.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.40 | 3.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.37 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.28 | 2.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.25 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.73 | 2.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.58 | 1.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.35 | 1.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.71 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.54 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,055.01 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $415.30 | 31 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $331.00 | 19 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $215.82 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $204.37 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $197.10 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $166.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $115.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.59 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.98 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.14 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.40 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $59.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.28 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| ISTURISA isturisa |
2025 | Isturisa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 31 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| RECORDATI_RARE_DISEASES_INC. Exact reporting entity; no affiliate inference |
2025 | ISTURISA open payments reported associated product |
CMS Open Payments — General Payments 7831 supporting records · 3061 recipient NPIs · example record 1181711288 |
Isturisa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 125 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 49 |
| Losartan Potassium | Losartan Potassium | 110 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 33 |
| Gabapentin | Gabapentin | 95 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 38 |
| Famotidine | Famotidine | 74 | 23 |
| Metformin Hcl | Metformin Hcl | 61 | 24 |
| Jardiance | Empagliflozin | 60 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Omeprazole | Omeprazole | 56 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 51 | 19 |
| Entresto | Sacubitril/Valsartan | 51 | 17 |
| Furosemide | Furosemide | 49 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Atenolol | Atenolol | 43 | suppressed |
| Ozempic | Semaglutide | 43 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Alendronate Sodium | Alendronate Sodium | 40 | 19 |
| Folic Acid | Folic Acid | 40 | 18 |
| Trazodone Hcl | Trazodone Hcl | 40 | 12 |
| Xarelto | Rivaroxaban | 40 | 16 |
| Alprazolam | Alprazolam | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Azithromycin | Azithromycin | 38 | 36 |
| Kerendia | Finerenone | 38 | suppressed |
| Lisinopril | Lisinopril | 37 | 14 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 18 |
| Korlym | Mifepristone | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 13 |
| Methylprednisolone | Methylprednisolone | 33 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 13 |
| Ibuprofen | Ibuprofen | 32 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 13 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | 11 |
| Naproxen | Naproxen | 27 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Cephalexin | Cephalexin | 21 | 20 |
| Meloxicam | Meloxicam | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Dexamethasone | Dexamethasone | 19 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Carvedilol | Carvedilol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Isturisa | Osilodrostat Phosphate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,055.01 · 101 records | Corcept Therapeutics | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Kerendia, Korlym, OTEZLA, Ozempic, RECORLEV, REPATHA, REXULTI, TRELEGY ELLIPTA, VERQUVO, VRAYLAR, VYALEV, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error